BioCentury
ARTICLE | Clinical News

Sotio reports PFS data from Phase II of ovarian cancer immunotherapy

June 1, 2018 7:22 PM UTC

Sotio a.s. (Prague, Czech Republic) reported interim data from the Phase II SOV01 trial to treat epithelial ovarian carcinoma showing that first-line treatment with DCVAC/OvCa given sequentially after carboplatin and paclitaxel significantly improved median progression-free survival (PFS) vs. DCVAC/OvCa given in parallel with chemotherapy and vs. chemotherapy alone (24.3 months vs. 18.3 and 18.6 months, respectively, p=0.05 for both). The open-label, European trial enrolled 92 patients with newly diagnosed epithelial ovarian carcinoma following radical debulking surgery. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...